Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued (2017 - 2025)

Crinetics Pharmaceuticals has reported Shares Issued over the past 9 years, most recently at $2.9 million for Q2 2025.

  • Quarterly results put Shares Issued at $2.9 million for Q2 2025, up 42.08% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 99.79% YoY), and the annual figure for FY2024 was $985.0 million, up 166.54%.
  • Shares Issued for Q2 2025 was $2.9 million at Crinetics Pharmaceuticals, down from $952.2 million in the prior quarter.
  • Over the last five years, Shares Issued for CRNX hit a ceiling of $952.2 million in Q4 2024 and a floor of -$112.5 million in Q4 2022.
  • Median Shares Issued over the past 5 years was $1.5 million (2022), compared with a mean of $105.9 million.
  • Peak annual rise in Shares Issued hit 275040.48% in 2022, while the deepest fall reached 15367.44% in 2022.
  • Crinetics Pharmaceuticals' Shares Issued stood at $737000.0 in 2021, then plummeted by 15367.44% to -$112.5 million in 2022, then surged by 427.44% to $368.4 million in 2023, then soared by 158.43% to $952.2 million in 2024, then crashed by 99.7% to $2.9 million in 2025.
  • The last three reported values for Shares Issued were $2.9 million (Q2 2025), $952.2 million (Q4 2024), and $48.3 million (Q3 2024) per Business Quant data.